Bone Mineral Homeostasis

cholecalciferol and ergocalciferol subclass

vitamin D metabolites and analogs

mechanism of action cholecalciferol and ergocalciferol

regulates gene transcription via the vitamin D receptor

clinical applications of cholecalciferol and ergocalciferol

vitamin D deficiency, osteoporosis, osteomalacia, psoriasis

clinical application of calcitriol

management of secondary hyperparathyroidism in patients with chronic kidney disease and for management of hypocalcemia in patients with hypoparathyroidism

clinical application of doxercalciferol

used for management of secondary hyperparathyroidism in patients with CKD

clinical application of paricalcitol

used for management of secondary hyperparathyroidism in patients with CKD

mechanism of action of paricalcitol

an analog of calcitriol

clinical application of paricalcitol

used for the management of secondary hyperparathyroidism in patients with CKD

subclass of calcipotriene

an analog of calcitriol approved for psoriasis

subclass of alendronate

bisphosphonates

mechanism of action of alendronate

suppresses the activity of osteoclasts and inhibits bone resorption

clinical application of alendronate

osteoporosis and Paget disease

other bisphosphonates

risedronate, ibandronate, pamidronate, zoledronate

subclass of teriparatide and abaloparatide

parathyroid hormone analog

mechanism of action of teriparatide and abaloparatide

acts through PTH receptors to produce a net increase in bone formation

clinical application of teriparatide and abaloparatide

osteoporosis

full length rhPTH

natpara

clinical application of natpara

used for hypoparathyroidism

mechanism of action of calcitonin

acts through calcitonin receptors to inhibit bone resorption

raloxifene subclass

Selective estrogen receptor modulator

mechanism of action of raloxifene

estrogen agonist effect in bone and estrogen ANTAGONIST effects in breast and endometrium

clinical applications of raloxifene

osteoporosis in postmenopausal women

denosumab subclass

RANK ligand (RANKL) inhibitor

mechanism of action of denosumab

binds to RANKL and prevents it from stimulating osteoclast differentiation and function

cinacalcet subclass

calcimimetic

mechanism of cinacalcet

activated calcium-sensing receptor

clinical application of cinacalcet

hyperparathyroidism

minerals that help with osteoporosis

calcium, phosphate, and strontium

mechanism of action of strontium

suppresses bone resorption

mechanism of action for calcium and phosphate

minerals required for bone mineralization

clinical application of calcium, phosphate, and strontium

osteoporosis, osteomalacia, calcium or phosphate deficiencies